A. Bradykinesia B. Rigidity C. Rest tremor D. Dementia

A. Unilateral symptoms (eg, greater on the right side than the left side) B. Cogwheel phenomenon C. Abnormal vertical eye movements D. Decreased facial expression

A. Order a brain magnetic resonance imaging to confirm the diagnosis of PD. B. Order laboratory testing to confirm the diagnosis of PD. C. Begin treatment with the goal of preventing or delaying progression of PD. D. Begin treatment with the goal of relieving symptoms of PD.

A. A monoamine oxidase B inhibitor B. An anticholinergic agent C. Amantadine D. Carbidopa/levodopa

A. No clinical trials have established that a pharmacologic therapy can modify the underlying course of PD. B. Clinical trials have provided clear evidence for disease modification, but no agents have yet been approved by the US Food and Drug Administration (FDA) for the indication of neuroprotection. C. The FDA recently approved the first disease-modifying therapy for patients with early PD. D. Currently there are over 15 FDA-approved agents with that are recognized to be efficacious in preventing clinical progression of PD.

A. Acetylcholine B. Serotonin C. Histamine D. Gamma-aminobutyric acid

A. Rest tremor B. Postural tremor C. Kinetic tremor D. All of the above

A. Nearly 80% of patients diagnosed with PD exhibit reactive depressive symptoms. B. The rate of suicide after a diagnosis of PD may be as high as 15%. C. An important goal of patient education is to reduce the risk of depression and suicide. D. Severe depression (major depressive disorder) is NOT a typical feature of early PD.

A. Rasagiline B. Selegiline C. Apomorphine D. Entacapone

A. Is a much higher risk with monoamine oxidase (MAO) A inhibitors than with MAO-B inhibitors at standard doses B. Is a much higher risk with MAO-A inhibitors than with MAO-B inhibitors C. Is of equal risk and common with all MAO inhibitors D. Is not usually an issue with either drug class because of the low drug doses used in PD treatment